Drug Trial Radar · NCT06559176
A Study of the Safety and Efficacy of Prime Editing (PM359) in Participants With p47phox Autosomal Recessive Chronic Granulomatous Disease (CGD )
Last checked: Nov 19, 2026Latest source record: Apr 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
12
Planned (sponsor's estimate)
Start
Oct 17, 2024
Primary completion
Jan 2030
Study completion Feb 2030
Sponsor
- Lead sponsor
- Prime Medicine, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, single-arm, multicenter Phase 1/2 study evaluating the safety and efficacy of gene therapy by transplantation of Prime Edited autologous CD34+ stem cells modified ex vivo (PM359) in participants with autosomal recessive Chronic Granulomatous Disease (CGD) caused by mutations in the NCF1 (Neutrophil Cytosolic Factor 1) gene.
Conditions
- Chronic Granulomatous Disease
- Granulomatous Disease, Chronic
Interventions
PM359Biological
Single dose of PM359 administered autologously by intravenous (I.V.) infusion following myeloablative conditioning with busulfan
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety of administration of PM359, as quantified by frequency of adverse events (AEs) after drug product infusionTime frame: PM359 infusion through Month 12 after PM359 infusion
- Percentage of participants with sustained reconstitution of NADPH oxidase activity in neutrophilsTime frame: At Month 6 and Month 12 after PM359 infusion, as compared to baseline
Locations
5 sites in 3 countries. Site status is shown where the registry gives one.
University of California Los Angeles Medical Center
Los Angeles, California
NIH Clinical Center
Bethesda, Maryland
The Children's Hospital at Tristar Medical Group/Sarah Cannon Center for Blood Cancers
Nashville, Tennessee
CHU - Sainte Justine Hospital
Montreal, Quebec, Canada
University College of London Hospital
London, England, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.